Atlas Trials

Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)

Clinical trial NCT05404139 · RECRUITING

Trial details

NCT number
NCT05404139
Sponsor
University Health Network, Toronto
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Prostate Cancer
Start date
2023-05-24
Primary completion
2031-02-01
Enrollment
352

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.